Penumbra, Inc. announced initial INSIGHT Registry data showing Penumbra's RED reperfusion catheters were successful in removing all clot types. Additionally, results of sub-analyses of the COMPLETE study showed use of the Penumbra System is effective for acute ischemic stroke (AIS) patients with tandem lesions, as well as patients who are considered in the late window of treatment. The results were presented at the 2022 World Federation of Interventional and Therapeutic Neuroradiology (WFITN) in Kyoto, Japan.

The initial INSIGHT Registry data evaluating Penumbra's latest RED reperfusion catheters in 161 AIS patients showed 68.9% had successful first-pass revascularization (mTICI=2b-3), and 97.0% had successful revascularization after final angiogram through site reported findings. Final mTICI=2b-3 scores were reported in 98.1% of patients with firm-red clots and in 100% of patients with other clot types. The INSIGHT Registry is a multicenter post-market evaluation.

COMPLETE is a global, prospective, multicenter post-market study assessing the performance of the company's Penumbra System. The Core Lab adjudicated findings include: Patients with anterior circulation tandem lesions with stenosis greater than 50% treated with Penumbra System resulted in successful revascularization: 89% of patients achieved mTICI 2b-3 and nearly 64% of patients achieved 90-day mRS 0-2. Late window patients achieved successful revascularization with the use of the Penumbra System in 83.2% of cases, with a 90-day good functional outcome rate of 55.4%. Additionally, there were no device related adverse events observed.